On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 37 cents.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share.
The biopharmaceutical company posted revenue of $1.2 million in the period, which also fell short of Street forecasts. Four analysts surveyed by Zacks expected $2.1 million.
In the final minutes of trading on Thursday, the company's shares hit $2.25. A year ago, they were trading at $6.30.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TTPH at https://www.zacks.com/ap/TTPH
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.